Reply to Letter Regarding Article, "Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure"
Author:
Affiliation:
1. Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University
Publisher
International Heart Journal (Japanese Heart Journal)
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Link
https://www.jstage.jst.go.jp/article/ihj/63/5/63_22-357/_pdf
Reference4 articles.
1. 1. Nakagawa Y, Imamura T. Letter by Nakagawa, et al. Regarding Article, "Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure" . Int Heart J 2022; 63: XX-XXX.
2. 2. Takami A, Kinugasa Y, Kamitani H, et al. Simple score to predict treatment response to low-dose tolvaptan in patients with heart failure. Int Heart J 2022; 63: 247-54.
3. 3. Hitomi Y, Nagatomo Y, Yukino M, et al. Characterization of tolvaptan response and its impact on the outcome for patients with heart failure. J Cardiol 2021; 78: 285-93.
4. 4. Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 2016; 31: 1650-8.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3